Incorporation of bevacizumab in the primary treatment of ovarian cancer.
暂无分享,去创建一个
B. Monk | R. Burger | M. Birrer | G. Fleming | R. Mannel | M. Brady | M. Bookman | J. Fowler | H. Homesley | B. Greer | Helen Q. Huang | M. Boente | S. Liang
[1] J. Yi,et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Tanoue. Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .
[3] Christian Marth,et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference , 2011, International Journal of Gynecologic Cancer.
[4] J. Yi,et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Yi,et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] U. Siebert,et al. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. , 2010, The oncologist.
[7] I. Kasman,et al. Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy , 2010, Clinical Cancer Research.
[8] A. Al-Attar,et al. Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies? , 2008, Clinical Cancer Research.
[9] G. Taraboletti,et al. Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion , 2008, Molecular Cancer Research.
[10] Michael W Sill,et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Howard Mackey,et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Monk,et al. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? , 2007, Gynecologic oncology.
[13] R. Kerbel. Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? , 2006, Science.
[14] D. Eton,et al. Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.
[15] R. Buller,et al. The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.
[16] Eleonora Marrazzo,et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy , 2005, Molecular Cancer Therapeutics.
[17] Napoleone Ferrara,et al. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.
[18] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[19] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[20] G. Yancopoulos,et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] G. Rustin,et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Cella,et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Y. Sugisaki,et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma , 2000, British Journal of Cancer.
[24] J. Wood,et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. , 2000, International journal of oncology.
[25] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[26] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[27] R. Dodge,et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] N. Ferrara,et al. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. , 1998, The American journal of pathology.
[29] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[30] L. Twiggs,et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma , 1997, Cancer.
[31] G. Viale,et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas , 1996, International journal of cancer.
[32] S. Steinberg,et al. Tumor angiogenesis in advanced stage ovarian carcinoma. , 1995, The American journal of pathology.
[33] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[34] Nitin R. Patel,et al. A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .
[35] R. Bast,et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.
[36] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[37] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[38] D.,et al. Regression Models and Life-Tables , 2022 .